Business
Exercise of Options
Exercise of Options.
About this update from Fusion Antibodies Plc
[{"type":"text","content":"\n \n \n RNS Number : 2933S\n Fusion Antibodies PLC\n 07 July 2020\n \n \n \n \n \n \n \n Fusion Antibodies plc\n \n \n (\"Fusion\" or the \"Company\")\n \n \n \n Exercise of Options \n \n \n Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that has made an application to the London Stock Exchange for the admission to trading on AIM (\"Admission\") of 12,500 new ordinary shares of 4p each in the Company (\"New Ordinary Shares\"). The New Ordinary Shares are being issued pursuant to the exercise of options by an employee of the Company. The options were granted pursuant to the Company's Historic Option Scheme (as defined in the Company's admission document dated 12 December 2017) and have an exercise price of 4p per option. The New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares and Admission is expected to become effective on or around 13 July 2020.\n \n \n \n \n Total Voting Rights\n \n \n \n \n \n On Admission, the issued share capital of the Company will consist of 25,437,025\n \n Ordinary Shares, with one voting right per share. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares and voting rights in the Company will be \n 25,437,025\n . The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.\n \n \n \n \n Enquiries:\n \n \n \n \n Fusion Antibodies plc\n \n \n www.fusionantibodies.com\n \n \n \n \n Dr Paul Kerr, Chief Executive Officer\n \n \n Via Walbrook PR\n \n \n \n \n James Fair, Chief Financial Officer\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Allenby Capital Limited\n \n \n Tel: +44 (0)20 3328 5656 \n \n \n \n \n James Reeve / Asha Chotai\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Walbrook PR\n \n \n Tel: +44 (0)20 7933 8780 or [email protected]\n \n \n \n \n Anna Dunphy\n \n \n Mob: +44 (0)7876 741 001\n \...